Matthew P. Pando
Algemeen Directeur bij Recognify Life Sciences, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Kristen MacFarlane | F | 60 |
Recognify Life Sciences, Inc.
Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Gary Walker | M | - |
Recognify Life Sciences, Inc.
Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Florian Brand | M | 37 |
Recognify Life Sciences, Inc.
Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Ryan Barrett | M | 43 |
Recognify Life Sciences, Inc.
Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Loïc Maurel | M | 69 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 jaar |
Philippe Rousseau | M | 53 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 6 jaar |
Laurent Condomine | M | 79 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Deborah A. Smeltzer | F | 70 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Christophe Jean | M | 67 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Patrick J. Langlois | M | 78 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Laurent Bracco | M | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Hervé Duchesne de Lamotte | M | 68 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 jaar |
Corinne Hoff | F | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Frédéric Joël Desdouits | M | 57 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 jaar |
Michel Picot | M | 72 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Isabelle Barber | M | 55 |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Frankrijk | 12 | 75.00% |
Verenigde Staten | 4 | 25.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Matthew P. Pando
- Persoonlijk netwerk